Indian Patent Office

An Invention Patent of Oriental Yuhong Granted by Australia

Retrieved on: 
Monday, June 26, 2023
Patent, Intellectual property, IP Australia, Building material, China National Intellectual Property Administration, Oriental Yuhong, Indian Patent Office, Research, Multimedia, Republic, Swimming, Water, United Kingdom, R, LTD, 3D printing

BEIJING, June 26, 2023 /PRNewswire/ -- Recently, the highly water-resistant, flexible cementitious coating of Oriental Yuhong obtained an invention patent certificate (Patent number: 2019413405) issued by IP Australia.

Key Points: 
  • BEIJING, June 26, 2023 /PRNewswire/ -- Recently, the highly water-resistant, flexible cementitious coating of Oriental Yuhong obtained an invention patent certificate (Patent number: 2019413405) issued by IP Australia.
  • Being innovative and practical, the coating has successively obtained invention patent certificates from the United States Patent and Trademark Office, the Indian Patent Office and the Patent Office of the People's Republic of China (now known as "China National Intellectual Property Administration"), with the patent number being US16720857, IN389530, and ZL201980078985.0 respectively.
  • The invention patent certificate issued by Australia marks a crucial step of Oriental Yuhong towards strengthening its advantages in independent intellectual property rights and protecting core patents.
  • Going ahead, Oriental Yuhong will take obtaining the invention patent authorization in Australia as an opportunity to continuously adhere to the vision "to be the most valuable global enterprise in the construction materials industry".

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

Retrieved on: 
Tuesday, April 4, 2023
Morph, Patent, Therapy, BCDA, Indian Patent Office, Boston Scientific, Torque, United States Patent Office fire, Orientation, Helix, Doctor of Philosophy, Medtronic, Acquisition, Patient, Arrhythmia, Pharmaceutical industry, Medical device, Juncus acutus, Avance

The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled “Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035.

Key Points: 
  • The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled “Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035.
  • The design enables the tensioning elements in the catheter to rotate around the catheter shaft, allowing consistent catheter performance in any direction.
  • The design is for a coil with a braid disposed coaxially about the coil, all embedded within the wall of an introducer sheath.
  • The coil enables a robust, kink-resistant design with enhanced column support, while the braid in the catheter shaft provides for excellent torque transmission.

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Retrieved on: 
Tuesday, June 14, 2022
ACST, PHN, Canadian Intellectual Property Office, PK, Marketing, IV, Securities Exchange Act of 1934, Drug Quality and Security Act, Patent, Nerve Damage, Postherpetic neuralgia, Skull, Bleeding, Neuropathic pain, Subarachnoid hemorrhage, Aneurysm, SubArachnoid Space, Bupivacaine, Indian Patent Office, FDA, Brain, Disability, Patient, GLOBE, Private Securities Litigation Reform Act, SAH, Review, COVID-19, Compliance, TSX, Risk, United States Patent and Trademark Office, Nimodipine, NASDAQ, SEC, Securities Act of 1933, A-T, Pharmaceutical industry, Vaccine, Ataxia–telangiectasia

Acasti recently reported positive results for a pharmacokinetic (PK) study, with intravenous GTX-104 meeting all endpoints.

Key Points: 
  • Acasti recently reported positive results for a pharmacokinetic (PK) study, with intravenous GTX-104 meeting all endpoints.
  • Acasti is now working with the U.S. FDA to commence a Phase 3 study on GTX-104, which is expected to be the final step required to seek regulatory approval.
  • Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases.
  • Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Proteum Energy® Issued Indian Patent for Reformation of Waste and Rich Natural Gas

Retrieved on: 
Wednesday, April 20, 2022
Alternative Energy, Energy, Oil, Gas, Indian Patent Office, Patent, Energy, CEO, Transport, Ethanol, Carbon, CO2, Power, Method, Methane, LLC, Natural gas, Industrial gas, Hydrogen

The new patent issued for refining assemblies and methods for rich natural gas supports the companys proprietary steam non-methane reforming (SnMR) technology which is used to produce clean hydrogen and low-carbon hydrogen-rich designer fuel blends.

Key Points: 
  • The new patent issued for refining assemblies and methods for rich natural gas supports the companys proprietary steam non-methane reforming (SnMR) technology which is used to produce clean hydrogen and low-carbon hydrogen-rich designer fuel blends.
  • Using this patented technology and other innovations, Proteum Energy can process waste gas, non-methane hydrocarbons and oxygenated hydrocarbons, such as ethanol, into clean hydrogen, low-carbon synthetic natural gas and CO2.
  • This patent positions Proteum Energy to help support India in its efforts to convert waste and rich natural gas and ethanol resources into clean hydrogen.
  • About Proteum Energy Headquartered in Phoenix Arizona, Proteum is a producer of low-cost clean hydrogen from waste and rich natural gas and renewable ethanol.

Proactive news headlines including Solis Minerals, International Graphite, Blackstone Minerals and Emyria Ltd

Retrieved on: 
Thursday, April 7, 2022
Stellar, Well, Palladium, AFC, Great Oxidation Event, Gold, CREA, Goal, GLOBE, European Public Real Estate Association, OTC, Cannabidiol, AOI, Proactivity, Sale, OTCQX, BSX, EMD, OpenNIC, IPO, SSH, Patent, Clinical trial, Mining, Social, ADN, ASX, Saindak Copper Gold Project, Uranium, CPH, OTCQB, DSF Refractories & Minerals Ltd, HHR, KOTH, Junta, ESG, TSX, CBD, Indian Patent Office, SLM, Social Security Government Pension Offset, DFS, Great, HRZ, Biophysical environment, Acquisition, Rare-earth element, Oil

Click here

Key Points: 
  • Click here
    Emyria Ltd (ASX:EMD) has started dosing participants in a clinical trial comparing EMD-RX5, its proprietary capsule of ultra-pure CBD, with the currently available Epidyolex.
  • Click here
    Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Tautachrome (OTC: TTCM) Gains Additional Patent Protections for its ARknet Platform with a New Augmented Reality Communities Patent Filing

Retrieved on: 
Monday, August 3, 2020
Intellectual property law, Patent law, United States patent law, International Searching and Preliminary Examining Authorities, Patent offices, Provisional application, United States Patent and Trademark Office, Patent application, Patent, Outline of patents, Indian Patent Office

This provisional patent was officially filed with the US Patent Office on Friday, July 31st, 2020.

Key Points: 
  • This provisional patent was officially filed with the US Patent Office on Friday, July 31st, 2020.
  • This filing allows for additional claims to be added to the patent application over the next 12 months, as new technology is developed and rolled out.
  • The ARknet social platform uses a multitude of geo-located 3D augmented reality objects across a single navigable network.
  • Tautachrome currently owns five granted US Patents for its KlickZie imagery technology and will continue to pursue internal IP development.

Provectus Biopharmaceuticals Expands Global Patent Portfolio to India for Cancer Combination Therapy

Retrieved on: 
Tuesday, June 9, 2020
Intellectual property law, Health sciences, International Searching and Preliminary Examining Authorities, Patent offices, Health, Cancer treatments, Checkpoint inhibitor, Immune system, Patent office, Cancer immunotherapy, Indian Patent Office, Patent application

Provectus further expands cancer combination therapy IP protection by filing new USPTO patent application for immunotherapy triplet combination of PV-10, CTLA-4, and PD-1

Key Points: 
  • Provectus further expands cancer combination therapy IP protection by filing new USPTO patent application for immunotherapy triplet combination of PV-10, CTLA-4, and PD-1
    KNOXVILLE, TN, June 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that the Indian Patent Office (IPO) has granted the Company's patent application for the combination of investigational autolytic cancer immunotherapy PV-10 and systemic immunomodulatory therapy, such as immune checkpoint blockade (CB).
  • The Company's cancer combination therapy patent estate provides intellectual property (IP) protection in a number of countries in Asia, Europe, and North America into the 2030s.
  • The new 2020 IPO patent award for cancer combination therapy follows the Companys IPO patent 297453, which was awarded in 2018 and protects Provectus proprietary manufacturing process used to produce the active pharmaceutical ingredient (API) in the Companys current and prospective investigational drug products.
  • The Company is the sole assignee for this new cancer combination therapy patent application.